Collegium Pharmaceutical Inc (NASDAQ:COLL) EVP Scott Dreyer sold 2,857 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $12.31, for a total value of $35,169.67. Following the completion of the transaction, the executive vice president now directly owns 40,596 shares in the company, valued at $499,736.76. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
COLL traded down $0.03 on Friday, hitting $11.40. 266,149 shares of the company were exchanged, compared to its average volume of 393,987. The company has a quick ratio of 1.19, a current ratio of 1.24 and a debt-to-equity ratio of 0.22. The business has a fifty day moving average price of $12.15. Collegium Pharmaceutical Inc has a fifty-two week low of $10.55 and a fifty-two week high of $21.20. The firm has a market capitalization of $415.33 million, a price-to-earnings ratio of -9.58 and a beta of 0.55.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.01. The company had revenue of $74.52 million for the quarter, compared to the consensus estimate of $70.10 million. Collegium Pharmaceutical had a negative net margin of 10.36% and a negative return on equity of 30.87%. On average, sell-side analysts predict that Collegium Pharmaceutical Inc will post -0.4 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the business. MERIAN GLOBAL INVESTORS UK Ltd acquired a new stake in shares of Collegium Pharmaceutical in the first quarter worth $26,000. First Quadrant L P CA bought a new position in shares of Collegium Pharmaceutical in the 1st quarter worth about $36,000. BNP Paribas Arbitrage SA lifted its position in shares of Collegium Pharmaceutical by 67,855.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,116 shares of the specialty pharmaceutical company’s stock worth $93,000 after buying an additional 6,107 shares during the last quarter. Oregon Public Employees Retirement Fund bought a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $103,000. Finally, Virginia Retirement Systems ET AL bought a new stake in Collegium Pharmaceutical in the 1st quarter valued at about $160,000. 94.15% of the stock is currently owned by institutional investors.
COLL has been the topic of several analyst reports. ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. BidaskClub cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Cantor Fitzgerald set a $135.00 price target on shares of Zimmer Biomet and gave the company a “buy” rating in a research note on Friday, April 26th. HC Wainwright reaffirmed a “buy” rating on shares of Ballard Power Systems in a research note on Friday, May 3rd. Finally, Janney Montgomery Scott began coverage on shares of PLx Pharma in a research note on Friday, April 12th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $26.17.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Featured Article: Overbought
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.